TITLE

Predictors of biologic treatment of psoriasis: a non-interventional study

AUTHOR(S)
Luis Puig; Tao Fan; Qian Ding; Smith, Nancy E.
PUB. DATE
January 2014
SOURCE
ClinicoEconomics & Outcomes Research;2014, Vol. 6, p93
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Biologic therapies represent a significant advance in the treatment of psoriasis. However, no studies have examined the patient characteristics predictive of biologic treatment of psoriasis. The purpose of this study was to ascertain the frequency and predictors of treatment of psoriasis with biologics in three European countries, ie, France, Spain, and the UK. Methods: This was a cross-sectional analysis of physician-recorded demographic and clinical data on patients receiving either conventional or biologic treatments for psoriasis. Data were drawn from the Adelphi 2007 Psoriasis Disease Specific Program (DSP®), a multinational, real-world survey of patients with psoriasis consulting practicing dermatologists. The numbers of patients treated with biologic and nonbiologic agents were recorded. Data were subjected to bivariate analysis according to treatment regimen (biologic versus nonbiologic). Predictors of treatment with biologics were identified by logistic regression analysis. Results: A total of 2,509 psoriasis patients were included in this study (1,374 from France, 561 from Spain, and 574 from the UK). Biologic use was most prevalent in Spain (19.4% of patients), followed by the UK (9.1%), and France (8.4%). In the logistic regression analysis, psoriatic arthritis was a statistically significant predictor of increased biologic use in France (odds ratio [OR] 5.38, 95% confidence interval [CI] 3.32-8.77), Spain (OR 2.71, 95% CI 1.16-6.33), and the UK (OR 8.70, 95% CI 3.65-20.83). Physician-assessed moderate-to-severe disease was also a statistically significant predictor of increased biologic use in France (OR 5.08, 95% CI 2.01-12.82), Spain (OR 11.11, 95% CI 4.33-28.57), and the UK (OR 8.55, 95% CI 1.11-66.67). Conclusion: In this study, an average of about one tenth of psoriasis patients enrolled in Spain, France, and the UK were treated with biologics in 2007. Physician-assessed moderate-to-severe disease and presence of psoriatic arthritis were significantly associated with biologic use in all three countries.
ACCESSION #
94750518

 

Related Articles

  • Predictors of biologic treatment of psoriasis: a non-interventional study. Puig, Luis; Tao Fan; Qian Ding; Smith, Nancy E. // ClinicoEconomics & Outcomes Research;2014, Vol. 6, p93 

    Background: Biologic therapies represent a significant advance in the treatment of psoriasis. However, no studies have examined the patient characteristics predictive of biologic treatment of psoriasis. The purpose of this study was to ascertain the frequency and predictors of treatment of...

  • Psoriasis and psoriatic: arthritis. Guttman, Cheryl // Dermatology Times;May2007 Psoriasis Supplement, Vol. 28, ps37 

    The article focuses on the results of a clinical trial designed to investigate the efficacy of adalimumab in treating patients with refractory psoriasis and psoriatic arthritis (PsA). According to doctor Marina Papoutsaki, the mean Psoriasis Area and Severity Index (PASI) score for the group...

  • Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis. Driessen, Rieke J. B.; De Jong, Elke M. G. J.; Salemink, Gerrit W.; Bürer, Jan H. G.; Van De Kerkhof, Peter C. M.; Van den Hoogen, Frank H. J. // Rheumatology;Mar2010, Vol. 49 Issue 3, p588 

    Objectives. To get the approval for reimbursement of biological therapies for PsA, patients need to fulfil specific criteria in many countries. The aim of this study was to evaluate the 4-year Dutch reimbursement application data, including the diagnostic, disease activity and response criteria...

  • Dead Sea.  // AirGuide Online.com;9/28/2009, p2 

    The article offers information on the features and leading attractions of the Dead Sea which is known as a unique combination of climatic conditions and elements in west Israel and east Jordan. The Dead Sea has proven to yield excellent natural treatments for a range of chronic ailments such as...

  • Secukinumab: Eruptive lentiginosis: case report.  // Reactions Weekly;6/22/2019, Vol. 1758 Issue 1, p313 

    No abstract available.

  • Impact of Biosimilars in Psoriasis Treatment. TORRES, Tiago; FILIPE, Paulo; SELORES, Manuela // Acta Medica Portuguesa;nov/dez2013, Vol. 26 Issue 6, p646 

    No abstract available.

  • Joint considerations. Hilton, Lisette // Dermatology Times;Aug2015 Supplement Dermatology Times, Vol. 36, p22 

    The article discusses treatment options for psoriasis and psoriatic arthritis ranging from tumor necrosis factor-alpha (TNF-alpha) blockers to Interleukin 12/23 inhibitors and Interleukin 17A drugs. Topics discussed include the efficacy of biologic therapies for psoriatric arthritis with TNF...

  • Global psoriatic arthritis market set to reach $US3.7bn by 2023.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 712 Issue 1, p37 

    The article reports on the increase of the global market for psoriatic arthritis therapies to about 66% to $U.S.3.7 billion in 2023 due to the continued uptake of premium-priced biologicals and novel therapies.

  • Etanercept efficacy for psoriatic arthritis sustained at 2 years.  // Formulary;Feb2004, Vol. 39 Issue 2, p74 

    Reports on the study presented at the American College of Rheumatology 67th Annual Scientific Meeting which concludes that Etanercept is effective for treating signs and symptoms of psoriatic arthritis and psoriasis for up to 106 weeks and also remains well-tolerated. Comments of Philip Mease...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics